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Background. In the literature conflicting opinions are detectable 
on the onset of adverse events as autoimmune disease post HPV 
vaccine and often case reports describes the onset of one of these 
events, but don’t emerge a clear relationship and we don’t have 
data to support it.
Methods. We carried out a systematic review to identify all sci-
entific publications dealing with the correlation between vaccine 
anti-papillomavirus and new onset of autoimmune diseases. We 
searched the main scientific databases (PubMed, Sciverse Sco-
pus, Web of knowledge and Cochrane Central Register of Con-
trolled Clinical Trials) for the following search terms: “vaccine”; 
“anti-papillomavirus”; “autoimmune”; “disease”; “disorder”. 
To evaluate the safety of HPV vaccines, the dichotomous data on 
the number of subjects experiencing an autoimmune disorder in 
the study vaccine group and the placebo group were extracted 
from each study with subsequent determination of the risk ratios 
and their 95% confidence intervals. We combined data statisti-
cally using a random effects model.
Results. We conduct a meta-analysis on six studies on bivalent 
and quadrivalent HPV vaccine. The total number of subjects 
included in the meta-analysis comprised 243,289 in the vaccine 
group and 248,820 in control groups. Four of the six trials had 
a Jadad score of 3 or 4 indicating an adequate trial quality. The 
most frequent autoimmune disease observed across the six studies 
were musculoskeletal,CNS conditions and endocrinological con-
ditions . The results of the meta-analysis demonstrated no corre-
lation between autoimmune disorders and HPV vaccines (pooled 
OR 1.038, 95% CI 0.689-1.562).
Conclusions. No correlation was identified for bivalent and 
quadrivalent HPV vaccines. It’s therefore essential to correctly 
inform the general population in order to try to increase both Ital-
ian and international vaccination coverage.
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Introduction
Human papillomavirus (HPV) is one of the commonest 
sexually transmitted viruses worldwide, with initial in-
fections typically occurring soon after sexual debut. To-
day more than 290 million women have a human papil-
lomavirus (HPV) infection. An effective vaccine is avail-
able as part of routine immunization programmes in 65 
countries. In low- and middle-income countries, where 
most cases of cervical cancer occur, if 70% vaccination 
coverage were achieved the deaths of more than 4 mil-
lion women would be avoidedover the next decade [1].
There are three vaccines currently available: one bivalent 
that protects against HPV types 6 and 11 which are the 
most common causes of genital warts,one quadrivalent, 
which also provides protection against HPV types  16 
and 18 and the last one nonavalent vaccine that contains 
serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58.. Despite 
this availability, the latest HPV vaccination coverage in 
USA estimates show that only 60 percent of adolescents 
aged 13-17 years have received one or more doses of 
HPV vaccine, with a gender gap in HPV vaccination 
rates (about 65 percent of females having received the 
first dose of HPV vaccine compared to 56 percent for 
males) and only 43 percent of adolescents are up to date 
with all recommended doses of HPV vaccine [2].
The most common reasons given for refusing the HPV 
vaccine were lack of vaccine endorsement by physi-
cians, lack of perceived need for the vaccine, lack of 
knowledge and safety concerns and caregivers’ concerns 
about safety or potential side effects [3-6].
One of the frequently attributed effects to the HPV vac-
cine that is cited in the literature is the onset of auto-
immune disease. Alleged associations between HPV 
vaccinations and autoimmune disorders (ADs) have 
been reported in the international literature and the most 
frequently proposed mechanism to account for these is 
molecular mimicry [7-11]. 
Objectives: in this study, we want to investigated wheth-
er the HPV vaccine is associated with the onset of ADs. 
Materials and methods
Search strategy and selection criteria
We carried out a systematic review to identify all case 
control study dealing with the correlation between vac-
cine anti-papillomavirus and new onset of autoimmune 
diseases.
This is “a condition in which the body recognizes its 
own tissues as foreign and directs an immune response 
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against them” such as gastroenteritis, connective tis-
sue disorders, alopecia, CNS conditions and endocrine 
autoimmune disease, etc… We searched the main sci-
entific databases (PubMed, Sciverse Scopus, Web of 
knowledge and Cochrane Central Register of Controlled 
Clinical Trials for the following search terms: “vac-
cine”; “anti-papillomavirus”; “autoimmune”; “disease”; 
“disorder”, using the function “AND” and “OR”. The 
bibliographies of all relevant articles, including reviews, 
were screened for further references. No language re-
strictions were imposed; papers in languages we were 
unable to read were translated using Google Translate. 
We developed the search terms in accordance with the 
Medical Subject Headings thesaurus, using a combina-
tion of test searches and via collaboration between inde-
pendent researchers and knowledge users. After delet-
ing duplicates, we further screened titles, abstracts, or 
entire articles using exclusion criteria. Screening was 
carried out independently by two authors (RS, CG). Any 
disagreement about eligibility between reviewers was 
resolved by a third author (VLF). The first two authors 
extracted data from included papers using a data extrac-
tion form reviewed by the other co-authors. These proce-
dures comply with the PRISMA guidelines for reporting 
systematic reviews [12].
Data extraction
Two independent reviewers (CG and RS) identified po-
tentially relevant articles and collected the following 
data: first author’s last name; year of publication; clini-
caltrials.govidentifier (if applicable); study design; total 
number of participants; age range; gender; disease back-
ground and study arms with number of vaccinated par-
ticipants in each arm. We found after this process only 
clinical trial for the purpose of our study, 
Evaluation of study quality
AD outcomes were identified from the included stud-
ies and considered for the meta-analysis. We used the 
Cochrane guidelines for systematic reviews of interven-
tions  [13] and two reviewers (CG, RS) independently 
assessed the quality of individual studies included in the 
meta-analysis. The Jadad scale for reporting randomised 
controlled trials (RCTs) was employed. This assigns an 
overall score of the methodological quality of a study 
from zero to five [14]. Although studies were not on the 
basis of this assessment, the quality scores were taken 
into account when describing results.
Data analysis
To evaluate the safety of HPV vaccines, the dichotomous 
data on the number of subjects experiencing an AD in 
the study vaccine group and the placebo group were ex-
tracted from each study with subsequent determination 
of the risk ratios (RR) and their 95% confidence inter-
vals (CI). We combined data statistically using a random 
effects model. I2 statistics and test Q di Cochran were 
used to assess the heterogeneity between the studies in-
cluded. Values of I2 can be interpreted as low (25-50%), 
moderate (50-75%), and high (75% and higher) levels 
of heterogeneity. Meta-analyses were performed using 
package "meta" rel.4.9 of the software R.
Dealing with missing data
Our analysis relies solely on existing data.
Assessment of reporting biases
Due to the limited number of studies available for meta-
analysis, assessment of publication bias was not applica-
ble. The review is subject to publication bias.
Results 
A total of 235 references were identified from electronic 
databases in the search performed on May 3 and 4, 2018 
(Fig. 1). Once duplicate entries (116) had been removed, 
references were further evaluated for inclusion based on 
the title and/or abstract. 119 potentially relevant articles 
were thereby included in the next stage for full-text eval-
uation. These publications included: 3 reviews, 8 animal 
studies,14 case reports, and 2 were studies regarding 
treatments; the other studies were position papers, letters 
comments and replies. The characteristics of the study 
population, interventions, control groups, the evaluated 
outcomes and/or design of the study (PICOS) failed to 
meet the inclusion criteria in 113 publications. Most of 
these studies were excluded as they did not include a 
control group. Ultimately, a total of six RCTs fulfilled 
all inclusion criteria and were selected for the meta-anal-
ysis [17-20].
Study characteristics
The main characteristics of the selected RCTs are sum-
marized in Table I.
Of the six studies selected, three used a bivalent vaccine 
and three a quadrivalent vaccine. The six vaccine trials 
on enrolled a total of 492,109 individuals, 243,289 in 
the treatment group (i.e. subjects administered vaccines) 
and 248,820 in the control groups (i.e. subjects receiving 
another vaccine (such as HBV vaccine, HA vaccine)or 
no vaccine). The age of the enrolled subjects in the nine 
studies varied from 9 to 26 years and all studies reported 
the number of subjects who experienced a specific AD. 
In the study by Geier et al. the vaccine adverse event 
reporting system (VAERS) database was examined for 
adverse event reports associated with vaccines admin-
istered from January 2006 through December 2012 to 
recipients between 18 and 39 years old with a listed resi-
dence in the USA and a specified female gender [15].
In the study by Block et al. females aged 9 to 26 years 
and males aged 9 to 16 years received at least 1 dose of 
HPV-6/11/16/18 vaccine or placebo and were studied for 
all serious and nonserious adverse events (AEFI) s and 
any new medical conditions were also recorded for the 
entire study period [18].
In the study by Verstraeten et al. AEFI data were col-
lected prospectively. In addition to a study-specific list 
of local or general events solicited during a brief pe-
riod following vaccination, unsolicited AEFI were cat-
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egorized as follows: non-serious AEFI, serious AEFI, 
medically significant events and new onset of chronic 
disease. These were reported to investigators during a 
study visit and were collected for 30 days after each vac-
cine dose [16].
In the study by Grimaldi-Bensouda a total of 113 spe-
cialized centers recruited (from December 2007 to April 
2011) females aged 14-26 years with incident cases of 
six types of ADs: idiopathic thrombocytopenic purpura 
(ITP), central demyelination/multiple sclerosis (MS), 
Guillain-Barrè syndrome, connective tissue disorders 
(systemic lupus erythematosus, rheumatoid arthritis/
juvenile arthritis), type  1 diabetes mellitus and auto-
immune thyroiditis. Control subjects matched to cases 
were recruited from general practice. Cases and controls 
were compared with regard to exposure to the quadriva-
lent HPV vaccine [17].
In the study by Willame et al. 9-25 year-old women after 
the first AS04-HPV-16/18 vaccine dose were compared 
to three unexposed cohorts and were observed with-
in the one year follow-up period  [20]. In the study by 
Angelo et al. three groups were considered: adolescent 
girls/women receiving HPV-16/18-vaccine alone (HPV 
group), subjects receiving HPV-16/18-vaccine coadmin-
istered with another vaccine and subjects receiving no 
vaccine (HVP group control) and unsolicited AEFI were 
reported for 30 days after each dose [19].
Study quality
The methodological quality of the included RCTs was 
satisfactory (Tab. I), except for those conducted by Geier 
and Verstraeten et al. Four out of the six studies (66.6%) 
had a score of 3 or 4 on the Jadad scale. The studies by 
Geier and Verstraeten et al scored 0 as no information 
was available about randomized method and blinding of 
these studies.
These publications included: 3 reviews, 8 animal stud-
ies,14 case reports, and 2 were studies regarding treat-
ments; the other studies were position papers, letters 
comments and replies.
HPV vaccine vs other vaccine or placebo  
or no vaccine
The most frequent ADs observed across the six studies 
were musculoskeletal (e.g. systemic lupus erythemato-
sus), CNS conditions and endocrinological conditions 
(especially thyroid disease). The results of the meta-
analysis demonstrated that ADs were not significantly 
more frequent in subjects receiving HPV vaccines 
than in those receiving placebos (pooled OR  1.038, 
95% CI 0.689-1.562 (Fig. 2).
The Cochran Q test (67.68; p < 0.001; GdL = 5) showed 
heterogeneity for many characteristics:variability, 
sample size in individual jobs etc. The Higgins index 
(92.61%) also showed significant heterogeneity. For this 
reason, the choice fell into a “random” model with an 
odds ratio of 1.038 and 95% CI of 0.689-1.562. 
Analysis of the forest plot reveals that almost all publi-
cations fall on the line of no effect, except for the study 
by David A. Geier (OR = 2.186; CI 95% 1.757-2.720), 
or 2.65% of vaccinated subjects with autoimmune dis-
Tab. I. Characteristics of the included studies.
Authors, 
year








22,011 9-26 5124 16887
Verstraetena, 
2008
68,512 > 10 36,744 31,768
Block,  
2010




1,365 14-26 269 1,096
Angelo,  
2014
47,857 9-25 27,353 20,504
Willame, 
2016
129,937 > 9 64,964 64,973
Fig. 1. Flowchart of the evaluation and inclusion process for the meta-analysis [21].
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ease versus 1.23% of unvaccinated subjects with autoim-
mune disease.
The funnel plot also showed a wide variability in the 
data (Fig. 3).
In the study by Geier et al. was observed that cases of 
autoimmune disease (such as gastroenteritis, arthritis, 
systemic lupus erythematosus, vasculitis, alopecia or 
CNS conditions) were significantly more likely than 
controls to have received the HPV4 vaccine. Casess with 
Guillain-Barre syndrome or thrombocytopenia were no 
more likely than controls to have received the HPV4 
vaccine [15]. In the study by Verstraeten et al. the auto-
immune events observed included thyroid disease (the 
most common ), LES, and neuroinflammation (multiple 
sclerosis and optic neuritis). For each disease category or 
for any individual event, most relative risks were close to 
1 and all the 95% CIs included. The overall relative risk 
was 0.92 (95% CI: 0.70, 1.22). The highest relative risk 
for an individual event was 2.39 for systemic lupus ery-
thematosus and the lowest were 0.53 for diabetes mel-
litus and nephritis. The 95% CIs of the relative risks of 
these events all included 1, suggesting no significantly 
increased or decreased risk following administration of 
the HPV-16/18 vaccine [16].
In the study by Block et al. no significant difference in 
AD rates were noted between vaccine and placebo re-
cipients The most common autoimmune conditions were 
arthralgia, hypothyroidism and psoriasis [18].
In the study by Grimaldi Bensouda et al. there was no 
evidence of an increased risk of the studied ADs follow-
ing vaccination with Gardasil within the time periods 
studied. The ADs included idiopathic thrombocytopenic 
purpura, central demyelination/multiple sclerosis, Guil-
lain-Barrè syndrome, connective tissue disorders, type 1 
diabetes mellitus and autoimmune thyroiditis [17].
In the study by Willame et al. the odds ratio (OR) 
(95% CI) of ADs was 1.41 in female and 1.77 in male 
cohorts when compared to the respective female and 
male historical cohorts. Secondary endpoints were eval-
uated for the following diseases with > 10 cases: Crohn’s 
disease (OR: 1.21 for female and 4.22 for male cohorts); 
autoimmune thyroiditis (OR:  3.75 for female and no 
confirmed cases for male cohorts) and type 1 diabetes 
(OR: 0.30 for female and 2.46 for male cohorts). Analy-
sis using confirmed and non-confirmed cases showed 
similar results, except for autoimmune thyroiditis in fe-
males, OR: 1.45 (0.79 to 2.64) [20].
In the study by Angelo et al. the incidence of unsolicited 
AEFI reported within 30 days after administration was 
similar between HPV and Control groups (30.8% and 
29.7%). The most frequently reported events within one 
year of administration were: psoriasis, Grave’s disease, 
autoimmune thyroiditis and vasculitis, rheumatoid ar-
thropathies and neuritis. The OR for each event showed 
no increased risk for women vaccinated with HPV vac-
cine [19].
Discussion
The objective of this meta-analysis was to assess the 
onset of autoimmune conditions related to HPV vac-
cines. References were included if they reported a RCT 
of HPV vaccines, including a placebo control group and 
gave information regarding the onset of ADs [15-20].
We identified three studies reporting on bivalent HPV 
vaccines and three studies on quadrivalent vaccines. The 
total number of subjects included in the meta-analysis 
comprised 243,289 in the vaccine group and 248,820 in 
control groups (another vaccine or no vaccine).
Four of the six trials had a Jadad score of 3 or 4 indicat-
ing an adequate trial quality [17-20].
ADs were reported by all studies. However, none of the 
observed events were considered to be related to the use 
of HPV vaccine.
The results of the meta-analysis should be interpreted 
with caution due to the several limitations.
First the number of the included clinical trials meeting 
the inclusion criteria was limited; second due to the dif-
ferent geographical locations of the RCTs included in 
our study and the Higgins index obtained, we chose a 
random-effects model for the meta-analysis which fur-
ther widens the confidence intervals. Differences in the 
Fig. 2. Forest plot. Fig. 3. Funnel plot.
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reporting method of observed ADs and the different ADs 
reported also limit the results of the study. 
Vaccine administration is usually safe and serious ad-
verse events rare. In the past, the hypothesis of a cor-
relation between the Hepatitis B vaccine and MS in ado-
lescents, supported by reports of temporal association 
between vaccine shot and disease onset was sufficient to 
fuel controversies on the use of vaccine in subjects with 
other ADs [21-24]. This lesson about the effect of publi-
cations about possible links between ADs and a vaccine 
should thus be considered when the safety of a vaccine 
is debated; the risk of misinterpretation of association is 
particularly high when we consider autoimmune disease 
and the HPV vaccine, because this vaccine is recom-
mended for young females (but also for males) in whom 
the incidence of autoimmune disease is high [25].
Therefore the role of pharmacovigilance surveillance 
remains of fundamental importance in allowing the sci-
entific community to detect unknown or rare events pos-
sibly related to the vaccine. 
A recent report highlighted the possible role of a ge-
netic predisposition to vaccine-induced autoimmune 
disease [26]. The presence of genetic bases for adverse 
events has been described for several drugs; perhaps one 
of the most important being the HLA-B*57:01 for a nucle-
oside inhibitors of reverse transcriptase (abacavir) [27]. 
The identification of genetic bases for adverse events 
following vaccination should be actively investigated 
as this would provide a useful tool to prevent rare and 
serious diseases without impacting negatively on public 
confidence in immunisation programmes. Furthermore, 
many cases of ADs reported in the literature were spo-
radic cases appearing in articles such as “case reports”. 
It is therefore necessary to clarify whether any relation 
exists between the administration of the vaccine and the 
onset of ADs (this would not seem to be so from our 
meta-analysis) or whether there is a mere coincidence in 
a subject destined to developed an ADs [28-30].
Today, concerns about vaccine safety have led some par-
ents to decline recommended vaccination of their chil-
dren, carrying to the spread of a phenomena called “vac-
cine hesitancy” and leading to the spread of diseases, as 
measles in Italy [31]. So study about the reassurance of 
vaccine safety remains critical for population health. In 
the literature, many reviews and meta-analysis analyzed 
the vaccine safety and one evidenced that there aren’t 
association between some vaccines and AEFI as autism 
and leukemia, but show an association with some vac-
cines, such as intussusception after rotavirus vaccine or 
febrile seizure post MMR or MMRV vaccine [32-34].
These AEFI are extremely rare, many factors could be 
implicated and should be evaluated against the protec-
tive benefits provided by the vaccines.
Conclusions
No major ADs were identified for bivalent and quadriva-
lent HPV vaccines. Therefore, further studies are need-
ed, particularly with accurately defined and reported 
safety outcomes to better evaluate the risks of these vac-
cines. In future, we also aim to investigate the implica-
tions of HPV vaccines for the most commonly reported 
individual ADs. 
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